Krka, d. d. (WSE:KRK)

Market Cap	31.24B +44.2%
Revenue (ttm)	8.61B +6.9%
Net Income	1.70B +13.0%
EPS	55.74 +13.9%
Shares Out	n/a
PE Ratio	18.36
Forward PE	18.23
Dividend	35.03 (3.41%)
Ex-Dividend Date	Jul 22, 2025

Volume	12
Average Volume	73
Open	1,050.00
Previous Close	1,028.00
Day's Range	1,040.00 - 1,050.00
52-Week Range	728.00 - 1,100.00
Beta	0.46
RSI	58.16
Earnings Date	May 14, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company’s prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolism, central nervous system, oncology, pain relief, antiinfectives for systemic use, antidiabetics, and other products. It provides non-prescription prod...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1954
• Employees: 13,236
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: KRK

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.

Financial numbers in EUR